Skip to content
HowShorted

TherapeuticsMD, Inc. short interest in 2020

In 2020, TherapeuticsMD, Inc.'s disclosed short interest ran from 31.49% of shares outstanding on 15 Jan 2020 to 28.19% on 31 Dec 2020, a change of -3.30 percentage points. The year's high was 34.76% on 13 Mar 2020 and its low 28.19% on 31 Dec 2020, averaging 31.36% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 44.10 days on 30 Oct 2020. Full history: TherapeuticsMD, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TherapeuticsMD, Inc. in 2020

2020 in figures

Start of year
31.49% (15 Jan 2020)
End of year
28.19% (31 Dec 2020)
Change
-3.30 pp
High
34.76% (13 Mar 2020)
Low
28.19% (31 Dec 2020)
Average
31.36%
Highest days to cover
44.10 (30 Oct 2020)
SEC filings marked
9

Every report in 2020

TherapeuticsMD, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202031.49%33.23results (8-K)
31 Jan 202033.53%26.85
14 Feb 202033.54%32.58
28 Feb 202033.42%15.05results (8-K), 10-K filed
13 Mar 202034.76%26.07
31 Mar 202032.74%19.60
15 Apr 202031.42%19.45
30 Apr 202029.97%17.93
15 May 202030.19%17.4610-Q filed, results (8-K)
29 May 202030.31%20.69
15 Jun 202030.55%12.24
30 Jun 202030.50%21.44
15 Jul 202030.54%18.85
31 Jul 202031.45%15.38
14 Aug 202032.65%18.90results (8-K), 10-Q filed
31 Aug 202032.56%41.61
15 Sep 202031.83%39.64
30 Sep 202031.48%32.56
15 Oct 202031.22%37.69
30 Oct 202030.59%44.10
13 Nov 202030.29%21.4210-Q filed, results (8-K)
30 Nov 202030.37%22.88
15 Dec 202029.04%12.52
31 Dec 202028.19%14.65

See also: TherapeuticsMD, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.